- Frencken’s 2024 earnings of S$37m (+14% y-o-y) were in line with our expectations, forming 100% of our full-year forecast. The results improvement was driven by 7% y-o-y revenue growth as well as gross margin improvement.
- - Read this at SGinvestors.io -
Revenue growth across 3 key segments offset by drop in automotive and industrial automation revenues.
- Frencken’s 2024 revenue grew 7% y-o-y, mainly driven by the semiconductor (+29% y-o-y), analytical life sciences (+7%) and medical (+2%) segments.
- Growth in the semiconductor segment was driven by increased orders from a key customer in Europe and continued recovery in sales from the Asia operations.
- The analytical life sciences segment saw higher sales from a key customer in Europe.
- - Read this at SGinvestors.io -
Semiconductor industry expected to continue path to recovery.
- Amid economic uncertainties, Frencken holds a cautiously optimistic stance and expects to post higher revenue in 1H25 compared to 2H24, with segment performances as follows:
- semiconductor: higher revenue,
- medical: stable revenue,
- analytical life sciences: stable revenue,
- industrial automation: stable revenue, and
- automotive: stable revenue.
- The global economic outlook remains uncertain, but the semiconductor industry is expected to continue the path to recovery. The overall long-term outlook for the chip sector also remains positive even though volatility may persist.
To navigate the shifting landscape, Frencken believes in building resilience & ensuring adaptability.
- Read more at SGinvestors.io.
